TY  - JOUR
AU  - Jelicić, Jelena
AU  - Todorovic-Balint, Milena
AU  - Perunicić-Jovanović, Maja
AU  - Boricić, Novica
AU  - Micev, Marjan
AU  - Stojsić, Jelena
AU  - Antić, Darko
AU  - Anđelić, Boško
AU  - Bila, Jelena
AU  - Balint, Bela
AU  - Pavlović, Sonja
AU  - Mihaljević, Biljana
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/944
AB  - Prognostic significance of immune microenvironment has been emphasized using the most advanced analysis, with consecutive attempts to reveal prognostic impact of this findings. The aim of this study was to compare and define prognostic significance of clinical parameters, microvessel density (MVD) in tumour tissue and expression of CD44s as adhesive molecule on tumour cells in diffuse large B cell lymphoma-DLBCL, primary central nervous system DLBCL-CNS DLBCL and follicular lymphoma-FL. A total of 202 histopathological samples (115 DLBCL/65 FL/22 CNS DLBCL) were evaluated. Overall response (complete/partial remission) was achieved in 81.3 % DLBCL patients, 81.8 % primary CNS DLBCL and 92.3 % FL. Absolute lymphocyte count-ALC/Absolute monocyte count-AMC  gt  2.6 in DLBCL and ALC/AMC a parts per thousand yenaEuro parts per thousand 4.7 in FL were associated with better event-free survival (EFS) and overall survival (OS) (p  lt  0.05). In DLBCL, MVD  gt  42 blood vessels/0.36 mm(2) correlated with primary resistant disease (p  lt  0.0001), poorer EFS and OS (p = 0.014). High CD44s expression in FL correlated with inferior EFS and OS (p  lt  0.01). In DLBCL, multivariate Cox regression analysis showed that ALC/AMC was independent parameter that affected OS (HR 3.27, 95 % CI 1.51-7.09, p = 0.003) along with the NCCN-IPI (HR 1.39, 95 % CI 1.08-1.79, p = 0.01). Furthermore, in FL, ALC/AMC mostly influenced OS (HR 5.21, 95 % CI 1.17-23.21, p = 0.03), followed with the FLIPI (HR 3.98, 95 % CI 1.06-14.95, p = 0.041). In DLBCL and FL, ALC/AMC is simple and robust tool that is, with current prognostic scores, able to define long-term survival and identify patients with inferior outcome. The introduction of immunochemotherapy might altered the prognostic significance of microenvionmental biomarkers (MVD and CD44s).
PB  - Springer, Dordrecht
T2  - Pathology & Oncology Research
T1  - The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas
EP  - 577
IS  - 3
SP  - 567
VL  - 22
DO  - 10.1007/s12253-015-0032-7
ER  - 

@article{
author = "Jelicić, Jelena and Todorovic-Balint, Milena and Perunicić-Jovanović, Maja and Boricić, Novica and Micev, Marjan and Stojsić, Jelena and Antić, Darko and Anđelić, Boško and Bila, Jelena and Balint, Bela and Pavlović, Sonja and Mihaljević, Biljana",
year = "2016",
abstract = "Prognostic significance of immune microenvironment has been emphasized using the most advanced analysis, with consecutive attempts to reveal prognostic impact of this findings. The aim of this study was to compare and define prognostic significance of clinical parameters, microvessel density (MVD) in tumour tissue and expression of CD44s as adhesive molecule on tumour cells in diffuse large B cell lymphoma-DLBCL, primary central nervous system DLBCL-CNS DLBCL and follicular lymphoma-FL. A total of 202 histopathological samples (115 DLBCL/65 FL/22 CNS DLBCL) were evaluated. Overall response (complete/partial remission) was achieved in 81.3 % DLBCL patients, 81.8 % primary CNS DLBCL and 92.3 % FL. Absolute lymphocyte count-ALC/Absolute monocyte count-AMC  gt  2.6 in DLBCL and ALC/AMC a parts per thousand yenaEuro parts per thousand 4.7 in FL were associated with better event-free survival (EFS) and overall survival (OS) (p  lt  0.05). In DLBCL, MVD  gt  42 blood vessels/0.36 mm(2) correlated with primary resistant disease (p  lt  0.0001), poorer EFS and OS (p = 0.014). High CD44s expression in FL correlated with inferior EFS and OS (p  lt  0.01). In DLBCL, multivariate Cox regression analysis showed that ALC/AMC was independent parameter that affected OS (HR 3.27, 95 % CI 1.51-7.09, p = 0.003) along with the NCCN-IPI (HR 1.39, 95 % CI 1.08-1.79, p = 0.01). Furthermore, in FL, ALC/AMC mostly influenced OS (HR 5.21, 95 % CI 1.17-23.21, p = 0.03), followed with the FLIPI (HR 3.98, 95 % CI 1.06-14.95, p = 0.041). In DLBCL and FL, ALC/AMC is simple and robust tool that is, with current prognostic scores, able to define long-term survival and identify patients with inferior outcome. The introduction of immunochemotherapy might altered the prognostic significance of microenvionmental biomarkers (MVD and CD44s).",
publisher = "Springer, Dordrecht",
journal = "Pathology & Oncology Research",
title = "The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas",
pages = "577-567",
number = "3",
volume = "22",
doi = "10.1007/s12253-015-0032-7"
}

Jelicić, J., Todorovic-Balint, M., Perunicić-Jovanović, M., Boricić, N., Micev, M., Stojsić, J., Antić, D., Anđelić, B., Bila, J., Balint, B., Pavlović, S.,& Mihaljević, B.. (2016). The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas. in Pathology & Oncology Research
Springer, Dordrecht., 22(3), 567-577.
https://doi.org/10.1007/s12253-015-0032-7

Jelicić J, Todorovic-Balint M, Perunicić-Jovanović M, Boricić N, Micev M, Stojsić J, Antić D, Anđelić B, Bila J, Balint B, Pavlović S, Mihaljević B. The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas. in Pathology & Oncology Research. 2016;22(3):567-577.
doi:10.1007/s12253-015-0032-7 .

Jelicić, Jelena, Todorovic-Balint, Milena, Perunicić-Jovanović, Maja, Boricić, Novica, Micev, Marjan, Stojsić, Jelena, Antić, Darko, Anđelić, Boško, Bila, Jelena, Balint, Bela, Pavlović, Sonja, Mihaljević, Biljana, "The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas" in Pathology & Oncology Research, 22, no. 3 (2016):567-577,
https://doi.org/10.1007/s12253-015-0032-7 . .

TY  - JOUR
AU  - Todorovic-Balint, Milena
AU  - Jelicić, Jelena
AU  - Mihaljević, Biljana
AU  - Kostić, Jelena
AU  - Stanić, Bojana
AU  - Balint, Bela
AU  - Pejanović, Nadja
AU  - Lucić, Bojana
AU  - Tošić, Nataša
AU  - Marjanović, Irena
AU  - Stojiljković, Maja
AU  - Karan-Đurašević, Teodora
AU  - Perisić, Ognjen
AU  - Rakocević, Goran
AU  - Popović, Milos
AU  - Raicević, Sava
AU  - Bila, Jelena
AU  - Antić, Darko
AU  - Anđelić, Boško
AU  - Pavlović, Sonja
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/936
AB  - The existence of a potential primary central nervous system lymphoma-specific genomic signature that differs from the systemic form of diffuse large B cell lymphoma (DLBCL) has been suggested, but is still controversial. We investigated 19 patients with primary DLBCL of central nervous system (DLBCL CNS) using the TruSeq Amplicon Cancer Panel (TSACP) for 48 cancer-related genes. Next generation sequencing (NGS) analyses have revealed that over 80% of potentially protein-changing mutations were located in eight genes (CTNNB1, PIK3CA, PTEN, ATM, KRAS, PTPN11, TP53 and JAK3), pointing to the potential role of these genes in lymphomagenesis. TP53 was the only gene harboring mutations in all 19 patients. In addition, the presence of mutated TP53 and ATM genes correlated with a higher total number of mutations in other analyzed genes. Furthermore, the presence of mutated ATM correlated with poorer event-free survival (EFS) (p = 0.036). The presence of the mutated SMO gene correlated with earlier disease relapse (p = 0.023), inferior event-free survival (p = 0.011) and overall survival (OS) (p = 0.017), while mutations in the PTEN gene were associated with inferior OS (p = 0.048). Our findings suggest that the TP53 and ATM genes could be involved in the molecular pathophysiology of primary DLBCL CNS, whereas mutations in the PTEN and SMO genes could affect survival regardless of the initial treatment approach.
PB  - MDPI, Basel
T2  - International Journal of Molecular Sciences
T1  - Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses
IS  - 5
VL  - 17
DO  - 10.3390/ijms17050683
ER  - 

@article{
author = "Todorovic-Balint, Milena and Jelicić, Jelena and Mihaljević, Biljana and Kostić, Jelena and Stanić, Bojana and Balint, Bela and Pejanović, Nadja and Lucić, Bojana and Tošić, Nataša and Marjanović, Irena and Stojiljković, Maja and Karan-Đurašević, Teodora and Perisić, Ognjen and Rakocević, Goran and Popović, Milos and Raicević, Sava and Bila, Jelena and Antić, Darko and Anđelić, Boško and Pavlović, Sonja",
year = "2016",
abstract = "The existence of a potential primary central nervous system lymphoma-specific genomic signature that differs from the systemic form of diffuse large B cell lymphoma (DLBCL) has been suggested, but is still controversial. We investigated 19 patients with primary DLBCL of central nervous system (DLBCL CNS) using the TruSeq Amplicon Cancer Panel (TSACP) for 48 cancer-related genes. Next generation sequencing (NGS) analyses have revealed that over 80% of potentially protein-changing mutations were located in eight genes (CTNNB1, PIK3CA, PTEN, ATM, KRAS, PTPN11, TP53 and JAK3), pointing to the potential role of these genes in lymphomagenesis. TP53 was the only gene harboring mutations in all 19 patients. In addition, the presence of mutated TP53 and ATM genes correlated with a higher total number of mutations in other analyzed genes. Furthermore, the presence of mutated ATM correlated with poorer event-free survival (EFS) (p = 0.036). The presence of the mutated SMO gene correlated with earlier disease relapse (p = 0.023), inferior event-free survival (p = 0.011) and overall survival (OS) (p = 0.017), while mutations in the PTEN gene were associated with inferior OS (p = 0.048). Our findings suggest that the TP53 and ATM genes could be involved in the molecular pathophysiology of primary DLBCL CNS, whereas mutations in the PTEN and SMO genes could affect survival regardless of the initial treatment approach.",
publisher = "MDPI, Basel",
journal = "International Journal of Molecular Sciences",
title = "Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses",
number = "5",
volume = "17",
doi = "10.3390/ijms17050683"
}

Todorovic-Balint, M., Jelicić, J., Mihaljević, B., Kostić, J., Stanić, B., Balint, B., Pejanović, N., Lucić, B., Tošić, N., Marjanović, I., Stojiljković, M., Karan-Đurašević, T., Perisić, O., Rakocević, G., Popović, M., Raicević, S., Bila, J., Antić, D., Anđelić, B.,& Pavlović, S.. (2016). Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses. in International Journal of Molecular Sciences
MDPI, Basel., 17(5).
https://doi.org/10.3390/ijms17050683

Todorovic-Balint M, Jelicić J, Mihaljević B, Kostić J, Stanić B, Balint B, Pejanović N, Lucić B, Tošić N, Marjanović I, Stojiljković M, Karan-Đurašević T, Perisić O, Rakocević G, Popović M, Raicević S, Bila J, Antić D, Anđelić B, Pavlović S. Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses. in International Journal of Molecular Sciences. 2016;17(5).
doi:10.3390/ijms17050683 .

Todorovic-Balint, Milena, Jelicić, Jelena, Mihaljević, Biljana, Kostić, Jelena, Stanić, Bojana, Balint, Bela, Pejanović, Nadja, Lucić, Bojana, Tošić, Nataša, Marjanović, Irena, Stojiljković, Maja, Karan-Đurašević, Teodora, Perisić, Ognjen, Rakocević, Goran, Popović, Milos, Raicević, Sava, Bila, Jelena, Antić, Darko, Anđelić, Boško, Pavlović, Sonja, "Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses" in International Journal of Molecular Sciences, 17, no. 5 (2016),
https://doi.org/10.3390/ijms17050683 . .

TY  - JOUR
AU  - Bila, Jelena
AU  - Sretenović, Aleksandra
AU  - Jelicić, Jelena
AU  - Tošić, Nataša
AU  - Marjanović, Irena
AU  - Fekete, Marija Dencic
AU  - Antić, Darko
AU  - Todorovic-Balint, Milena
AU  - Marković, Olivera
AU  - Milojević, Zoran
AU  - Radojković, Milica
AU  - Trajković, Goran
AU  - Purić, Mila
AU  - Pavlović, Sonja
AU  - Mihaljević, Biljana
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/962
AB  - Within a personalized treatment approach in multiple myeloma (MM), the prognostic significance of cereblon (CRBN) expression was analyzed in 92 newly diagnosed patients. In patients treated with thalidomide-based combinations, CRBN expression significantly affected the treatment response (P = .028) and progression free survival (P = .017). With implications for the treatment outcome, measurement of CRBN expression might represent an additional prognostic tool in a personalized treatment approach. Background: To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon (CRBN) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MM patients ineligible for autologous stem cell transplantation (ASCT). Patients and Methods: The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26.1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively. Results: A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression (P = .006), mainly in the patients treated with thalidomide (P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients (P = .012). Conclusion: CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach.
PB  - CIG Media Group, Lp, Dallas
T2  - Clinical Lymphoma Myeloma & Leukemia
T1  - Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma
EP  - 615
IS  - 11
SP  - 610
VL  - 16
DO  - 10.1016/j.clml.2016.08.007
ER  - 

@article{
author = "Bila, Jelena and Sretenović, Aleksandra and Jelicić, Jelena and Tošić, Nataša and Marjanović, Irena and Fekete, Marija Dencic and Antić, Darko and Todorovic-Balint, Milena and Marković, Olivera and Milojević, Zoran and Radojković, Milica and Trajković, Goran and Purić, Mila and Pavlović, Sonja and Mihaljević, Biljana",
year = "2016",
abstract = "Within a personalized treatment approach in multiple myeloma (MM), the prognostic significance of cereblon (CRBN) expression was analyzed in 92 newly diagnosed patients. In patients treated with thalidomide-based combinations, CRBN expression significantly affected the treatment response (P = .028) and progression free survival (P = .017). With implications for the treatment outcome, measurement of CRBN expression might represent an additional prognostic tool in a personalized treatment approach. Background: To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon (CRBN) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MM patients ineligible for autologous stem cell transplantation (ASCT). Patients and Methods: The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26.1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively. Results: A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression (P = .006), mainly in the patients treated with thalidomide (P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients (P = .012). Conclusion: CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach.",
publisher = "CIG Media Group, Lp, Dallas",
journal = "Clinical Lymphoma Myeloma & Leukemia",
title = "Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma",
pages = "615-610",
number = "11",
volume = "16",
doi = "10.1016/j.clml.2016.08.007"
}

Bila, J., Sretenović, A., Jelicić, J., Tošić, N., Marjanović, I., Fekete, M. D., Antić, D., Todorovic-Balint, M., Marković, O., Milojević, Z., Radojković, M., Trajković, G., Purić, M., Pavlović, S.,& Mihaljević, B.. (2016). Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma. in Clinical Lymphoma Myeloma & Leukemia
CIG Media Group, Lp, Dallas., 16(11), 610-615.
https://doi.org/10.1016/j.clml.2016.08.007

Bila J, Sretenović A, Jelicić J, Tošić N, Marjanović I, Fekete MD, Antić D, Todorovic-Balint M, Marković O, Milojević Z, Radojković M, Trajković G, Purić M, Pavlović S, Mihaljević B. Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma. in Clinical Lymphoma Myeloma & Leukemia. 2016;16(11):610-615.
doi:10.1016/j.clml.2016.08.007 .

Bila, Jelena, Sretenović, Aleksandra, Jelicić, Jelena, Tošić, Nataša, Marjanović, Irena, Fekete, Marija Dencic, Antić, Darko, Todorovic-Balint, Milena, Marković, Olivera, Milojević, Zoran, Radojković, Milica, Trajković, Goran, Purić, Mila, Pavlović, Sonja, Mihaljević, Biljana, "Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma" in Clinical Lymphoma Myeloma & Leukemia, 16, no. 11 (2016):610-615,
https://doi.org/10.1016/j.clml.2016.08.007 . .